A Study to Test a New Immunotherapy, ABX-001, Alone and in Combination With the Marketed Drug, Pembrolizumab, for the Treatment of Tumors Previously Treated With Other Therapies

Recruiting

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(5 sites)

Germany

Charite-Universitaetsmedizin Berlin - Campus Benjamin Franklin (CBF), Berlin

Universitaetsklinikum Tuebingen, Tübingen

Spain

Vall d'Hebron Institut d'Oncologia, Barcelona

Hospital Universitario Fundacion Jimenez Diaz, Madrid

The START Center for Cancer Care - CIOCC, Madrid